[ET Net News Agency, 31 October 2019] Sino Biopharmaceutical Limited (01177) said
oncology medicine "Lenalidomide Capsules" of Chia-Tai Tianqing Pharmaceutical Group Co.,
Ltd, a subsidiary of the company, has obtained the approval for Consistency of Quality and
Efficacy Evaluation for Generic Drugs granted by the National Medical Products
Administration of the People's Republic of China.
Lenalidomide is indicated for the treatment of patients with multiple myeloma who have
received at least one other form of treatment. (RC)